NXT Biologics
Biotechnology company developing broad-spectrum (pan‑fungal) immunotherapies including a recombinant protein vaccine and monoclonal antibody therapeutics. The organization conducts preclinical efficacy and immunogenicity studies in murine and non-human primate models, pursues process development and formulation activities, publishes peer‑reviewed research, and seeks strategic partnerships to advance development.
Industries
Nr. of Employees
small (1-50)
Products
Pan‑fungal vaccine (recombinant protein)
A recombinant protein vaccine designed to induce durable systemic and mucosal antibody responses that provide cross‑protection against multiple fungal pathogens in preclinical models.
Pan‑fungal monoclonal antibody therapeutics
Monoclonal antibodies under development aimed at treating life‑threatening invasive fungal infections caused by multiple fungal species.
Pan‑fungal vaccine (recombinant protein)
A recombinant protein vaccine designed to induce durable systemic and mucosal antibody responses that provide cross‑protection against multiple fungal pathogens in preclinical models.
Pan‑fungal monoclonal antibody therapeutics
Monoclonal antibodies under development aimed at treating life‑threatening invasive fungal infections caused by multiple fungal species.
Services
Engagement with external partners and funders to advance development of anti‑fungal vaccines and immunotherapeutics.
Engagement with external partners and funders to advance development of anti‑fungal vaccines and immunotherapeutics.
Expertise Areas
- Vaccine development (recombinant protein)
- Monoclonal antibody therapeutics
- Preclinical efficacy testing
- Immunology and immunogenicity assessment
Key Technologies
- Recombinant protein vaccines
- Monoclonal antibody platforms
- Murine and non-human primate disease models
- Mucosal immunology assays
News & Updates
A national infectious disease institute awarded a contract for process development and formulation work to begin in 2024 to support vaccine advancement.
Press coverage summarizing preclinical results showing protection against vaginal yeast infection in mice and broader pan‑fungal activity.
Peer‑reviewed publication reporting protective efficacy of the pan‑fungal vaccine in a murine vulvovaginitis model.
Peer‑reviewed publication demonstrating active and passive immunization with the pan‑fungal vaccine reduced disease in an immunosuppressed murine model of systemic infection.
Peer‑reviewed article describing immunogenicity and protective efficacy in models of aspergillosis, candidiasis and pneumocystosis.
Awarded a contract by a national infectious disease institute to perform process development and formulation of the pan‑fungal vaccine to begin in 2024.
A national infectious disease institute awarded a contract for process development and formulation work to begin in 2024 to support vaccine advancement.
Press coverage summarizing preclinical results showing protection against vaginal yeast infection in mice and broader pan‑fungal activity.
Peer‑reviewed publication reporting protective efficacy of the pan‑fungal vaccine in a murine vulvovaginitis model.
Peer‑reviewed publication demonstrating active and passive immunization with the pan‑fungal vaccine reduced disease in an immunosuppressed murine model of systemic infection.
Peer‑reviewed article describing immunogenicity and protective efficacy in models of aspergillosis, candidiasis and pneumocystosis.
Awarded a contract by a national infectious disease institute to perform process development and formulation of the pan‑fungal vaccine to begin in 2024.